Categoria: Abstract

Home / Abstract
Concomitant RAS and BRAF mutations in mCRC patients as prognostic and predictive factor
Articolo

Concomitant RAS and BRAF mutations in mCRC patients as prognostic and predictive factor

Pretta A, Ziranu P, Spanu D, et al. Background: RAS and BRAF alterations are both prognostic and predictive factors in metastatic colorectal cancer. Recent literature has described cases of RAS and BRAF mutations (mut) coexistence in colorectal cancer. This association appears to be related to poor median overall survival (mOS), median progression free survival (mPFS)...

Pattern of disease progression in BRAF V600E-mutant mCRC trated with encoafenib and cetuximab: a single institution analysis
Articolo

Pattern of disease progression in BRAF V600E-mutant mCRC trated with encoafenib and cetuximab: a single institution analysis

Chiaravalli M, Anghelone A, Beccia V, et al. Background: EC combination is the new standard of care (SOC) for previously treated BRAF V600E-mutant mCRC. Despite the superiority compared to the previous SOC, efficacy is disappointing in terms of duration of response. We have investigated whether the new patterns of response and progression to novel drugs, reported by...

Modified folfoxiri plus panitumumab vs MFOLFOX6/PAN as initial treatment of unresactable RAS/BRAF wild-type mCRC: results of the TRIPLETE study by GONO
Articolo

Modified folfoxiri plus panitumumab vs MFOLFOX6/PAN as initial treatment of unresactable RAS/BRAF wild-type mCRC: results of the TRIPLETE study by GONO

Rossini D, Antoniotti C, Bergamo F, et al. Background: The association of a chemotherapy doublet (FOLFOX/FOLFIRI) with an anti-EGFR monoclonal antibody (cetuximab or panitumumab) is an upfront option for the treatment of RAS and BRAF wt mCRC patients. Phase II studies investigating FOLFOXIRI with an anti-EGFR reported promising activity results and an acceptable safety profile...

Folfoxiri/bevacizumab with nivolumab as first line therapy in mCRC with RAS/BRAF mutations, regardeless of microsatellite status: results of NIVACOR trial
Articolo

Folfoxiri/bevacizumab with nivolumab as first line therapy in mCRC with RAS/BRAF mutations, regardeless of microsatellite status: results of NIVACOR trial

Demato A, Bergamo F, Antonuzzo L, et al. Background: FOLFOXIRI/BEV represents a standard approach in the 1L setting of pts with mCRC, especially RAS/BRAF mutated (mut). The NIVACOR study (NCT04072198) aims to evaluate NIV added to FOLFOXIRI/BEV as first-line therapy in mCRC RAS/BRAF mut pts, regardless of MSS/MSI status. Methods: This is a single-arm, multicenter, open-label, phase II trial in...

Prospective evaluation of emergent RAS and BRAF mutations in pre-trated mCRC patients candidate to anti-EGFR retreatment: preliminary findings from the PARERE study
Articolo

Prospective evaluation of emergent RAS and BRAF mutations in pre-trated mCRC patients candidate to anti-EGFR retreatment: preliminary findings from the PARERE study

Germani MM, Rossini D, Vetere G, et al. Background: Retreatment (re-tx) with anti-EGFRs is a promising strategy in RAS/BRAF wild-type (wt) anti-EGFR pre-treated metastatic colorectal cancer patients (mCRC pts), provided that no mechanisms of acquired resistance to anti-EGFRs are found in circulating tumor DNA (ctDNA). The phase II single arm CHRONOS study showed a 31% prevalence...

mCRC patients treated with upfront chemotherapy + bevacizumab within TRIBE and TRIBE2 studies: a focus on primary tumor resection
Articolo

mCRC patients treated with upfront chemotherapy + bevacizumab within TRIBE and TRIBE2 studies: a focus on primary tumor resection

Fanotto V, Conca V, Casagrande M, et al. Background: Management of primary tumor in mCRC pts still remain an intricate and complex issue for oncologists, especially in case of asymptomatic pts and during therapy with antiangiogenic drugs. The present analysis focused on the role of PTR in a pooled analysis of two randomized phase III studies (TRIBE...

Prognostic value of a risk score system for metastatic mucinous CRC: an exploratory study
Articolo

Prognostic value of a risk score system for metastatic mucinous CRC: an exploratory study

Catalano V, De Grandis MC, Cremolini C, et al. Background: In metastatic colorectal cancer (MCRC), mucinous histology has been associated with poor response rate and prognosis. However, data are controversial (Catalano et al, 2020) and outcome is quite heterogeneous. The aim of the present study was to assess prognostic factors in mucinous MCRC and construct an exploratory prognostic...

EGFR-based induction therapy in patients with RAS wild type mCRC
Articolo

EGFR-based induction therapy in patients with RAS wild type mCRC

Raimondi A, Morano F, Trarbach T, Karthaus M, et al. Background: In mCRC, fluoropyrimidine plus bevacizumab is the recommended maintenance after first-line bevacizumab-based doublet/triplet chemotherapy. Anti-EGFR agents and doublet chemotherapy is a guideline-endorsed upfront option for RAS/BRAF wild-type (wt) mCRC patients, with no clear definition of the optimal post-induction strategy and maintenance schedule. Several phase II RCTs investigated...

Genomic mechanisms of acquired resistance of patients with BRAF V600E-mutant metastatic colorectal cancer treated in the BEACON study
Articolo

Genomic mechanisms of acquired resistance of patients with BRAF V600E-mutant metastatic colorectal cancer treated in the BEACON study

Kopetz S, Murphy DA, Pu J, et al. Background: In the randomized phase III BEACON study (NCT02928224), encorafenib + cetuximab ± binimetinib regimens improved overall survival and objective response rate vs standard of care (control) in pts with previously treated BRAF V600E-mt mCRC. To assess the genomic landscape of resistance, we profiled circulating tumor DNA (ctDNA) in...

Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): a systematic literature review and meta-analysis of clinical outcomes
Articolo

Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): a systematic literature review and meta-analysis of clinical outcomes

Bekaii-Saab T, Lach K, Hsu LI, et al. Background: HER2 overexpression/amplification in patients with RAS wild-type (WT) mCRC may be associated with resistance to standard of care anti-EGFR therapies. However, there are no meta-analyses investigating this association. Our objective was to assess the predictive effect of HER2 amplification/overexpression on anti-EGFR treatment outcomes. Methods: A systematic...